Lp(a): A Toolkit for Health Care Professionals

13 years revealed increasing major adverse coronary event rates from 0.30 to 0.54 (P=0.001) for y-2 to y-1 before LA, decline to 0.14 from y-1 to y+1 (P<0.0001) and to 0.05 from y+1 to y+2 (P=0.014). In patients with Lp(a)-hyperlipoproteinemia, progressive cardiovascular disease and maximally tolerated lipid- lowering medication, LA effectively lowered the incidence rate of cardiovascular events, but only Lp(a) concentration appeared to comprehensively reflect Lp(a)- associated cardiovascular risk. 24 z PCSK9 inhibitors reduce LDL-C by 43% to 64% and also lower Lp(a) by 20% to 30%. Post-hoc analyses of the FOURIER (evolocumab) and ODYSSEY Outcome (alirocumab) trials demonstrated that independent of LDL-C reduction, evolocumab reduced risk of major adverse cardiovascular events (MACE) by 16%, and alirocumab lowered MACE risk by 0.6% for each 1 mg/dL improvement in Lp(a) levels. Neither the AHA/ACC nor